Share this post on:

product name Sorafenib Tosylate


Description: Sorafenib Tosylate,also known as BAY 43-9006, is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in enzymatic assays, respectively. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis. Sorafenib was approved in 2005 for the treatment of advanced renal cancer. 

References: Cancer Res, 2004, 64(19), 7099-7109.



Molecular Weight (MW)

637.03
Formula

C21H16ClF3N4O3.C7H8O3S
CAS No.

475207-59-1
Storage

-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)

DMSO: 127 mg/mL (199.4 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol: <1 mg/mL
Solubility (In vivo)

2% Cremophor EL, 2% N,N-dimethylacetamide: 30 mg/mL

other peoduct :

General Oral administration of Sorafenib tosylate (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity.
Animal model Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
Formulation Cremophor EL/ethanol (1:1) as 4-fold (4 × stock solution), and diluted to 1 × with w
Dosages 60 mg/kg
Administration Administered orally once a day
Reference [1] Wilhelm SM, et al. Cancer Res, 2004, 64(19), 7099-7109.

Sapitinib